Noble James 4
4 · LAVA Therapeutics NV · Filed Nov 17, 2025
Insider Transaction Report
Form 4
Noble James
Director
Transactions
- Disposition to Issuer
Share Options (Right to Buy)
2025-11-13−33,390→ 0 totalExercise: $0.93Exp: 2035-02-12→ Common Shares (33,390 underlying)
Footnotes (1)
- [F1]This option was cancelled pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the "Purchase Agreement") in exchange for cash and contingent value rights ("CVRs") (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option.